Revolution Medicines Begins Treating Patients In RASolute 305, Global, Randomized Phase 3 Clinical Trial Evaluating Zoldonrasib In Combination With Standard Of Care Chemotherapy As First Line Treatment In Patients With Metastatic RAS G12D PDAC

Loading news article.

Revolution Medicines Begins Treating Patients In RASolute 305, Global, Randomized Phase 3 Clinical Trial Evaluating Zoldonrasib In Combination With Standard Of Care Chemotherapy As First Line Treatment In Patients With Metastatic RAS G12D PDAC | WAPE

Revolution Medicines Begins Treating Patients In RASolute 305, Global, Randomized Phase 3 Clinical Trial Evaluating Zoldonrasib In Combination With Standard Of Care Chemotherapy As First Line Treatment In Patients With Metastatic RAS G12D PDAC

Article summary

Related companies

Comments —